LIVE WEBINAR: Friday, December 4, 2020, 3:00 PM – 4:30 PM Pacific Time (6:00 PM – 7:30 PM Eastern Time)

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Acute Myeloid Leukemia (Part 3 of a 4-Part Series)

A Friday Satellite Symposia Live Webinar Series Preceding the 62nd ASH Annual Meeting


Mark Levis, MD, PhD
Director, Adult Leukemia Program
Co-Division Director, Hematologic Malignancies
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Alexander Perl, MD
Associate Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Member, Leukemia Program
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania

Daniel A Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Robert H Allen, MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Eytan M Stein, MD
Assistant Attending Physician
Director, Center for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Andrew H Wei, MBBS, PhD
Adjunct Associate Professor
Department of Haematology
Alfred Hospital
Melbourne, Australia

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from AbbVie Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Helsinn Healthcare SA and Pfizer Inc.

Friday, December 4, 2020
3:00 PM – 4:30 PM PT (6:00 PM – 7:30 PM ET)
Live CME-accredited webinar

Topics to Be Discussed

  • Optimal Management of Acute Myeloid Leukemia (AML) in Older Patients or Those Ineligible for Intensive Chemotherapy
  • Treatment Options for Patients with AML Harboring FLT3 Mutations
  • Management of AML with IDH Mutation
  • Induction and Maintenance Therapy for Younger Patients with AML without Targetable Mutations
  • Other Novel Agents and Investigational Strategies for AML
A detailed agenda will be provided by November.

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Recognize the clinical and prognostic significance of specific cytogenetic and molecular abnormalities, and use this information to develop, adapt or refine current diagnostic testing algorithms for patients with AML.
  • Analyze how age, performance status and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with various presentations of AML.
  • Evaluate the recent FDA approval of venetoclax in combination with a hypomethylating agent or low-dose cytarabine for patients with newly diagnosed AML not eligible for intensive therapy, and discern how these regimens can be optimally integrated into nonresearch care algorithms.
  • Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML.
  • Develop an understanding of the mechanism of action of, published data with and current clinical role of available IDH1/2 inhibitors for patients with AML and an IDH1 or 2 mutation.
  • Consider Phase III data documenting the efficacy of CC-486 as maintenance therapy for patients with newly diagnosed AML who attained complete response or complete response with incomplete blood count recovery with induction chemotherapy, and discern how this novel strategy may affect future clinical decision-making.
  • Design and implement a plan of care to prevent, recognize and manage side effects and toxicities associated with recently approved systemic therapies in the management of AML to support quality of life and continuation of therapy.
  • Appraise ongoing clinical trials evaluating novel investigational approaches for AML, and obtain consent from appropriate patients for study participation.

CME Credit Form
A CME credit form will be emailed to participants within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AbbVie Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Helsinn Healthcare SA and Pfizer Inc.